|
WO2019236888A1
|
|
Systems and methods for fiber-based visible and near infrared optical coherence tomography
|
|
US2019365273A1
|
|
White matter fibrography by synthetic magnetic resonance imaging
|
|
US2019256567A1
|
|
Compositions and methods for diagnosing and/or treating kidney injury
|
|
AU2018279705A1
|
|
Anti-ROBO2 antibodies, compositions, methods and uses thereof
|
|
US2018280493A1
|
|
Methods and compositions using highly conserved pneumococcal surface proteins
|
|
US2018369336A1
|
|
B cell-based cancer immunotherapy
|
|
WO2017053718A2
|
|
Biomarkers for the early detection of parkinson's disease
|
|
WO2015179196A1
|
|
Aqueous contrast agents for dynamic mri and mra
|
|
WO2015031408A1
|
|
Multi-spectral mri scan with magnetization recovery
|
|
US9599605B1
|
|
Parkinson's disease model and methods
|
|
WO2014158669A1
|
|
A combination introducer and stylet
|
|
US2015299778A1
|
|
Primers, probes, and methods for mycobacterium tuberculosis specific diagnosis
|
|
US2015285789A1
|
|
Assays, systems, and methods for obtaining personalized anabolic profiles
|
|
WO2014070233A1
|
|
Brca1 mutations as predictive markers for topoisomerase i inhibitors
|
|
US2014173777A1
|
|
Methods for elevating fat/oil content in plants
|
|
US2014050711A1
|
|
Production of red blood cells and platelets from stem cells
|
|
NZ724430A
|
|
Slit-robo signaling for diagnosis and treatment of kidney disease
|
|
AU2013207484A1
|
|
SLIT-ROBO signaling for diagnosis and treatment of kidney disease
|
|
WO2011133658A1
|
|
Compositions and methods for targeting and delivering therapeutics into cells
|
|
EP2860195A1
|
|
Treatment of IgE-mediated disease
|
